Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-1701 + fluazopalil
- Development stage
- Unknown
- Lead developer
- Hengrui Therapeutics
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
SHR-1701 + fluazopalil is an investigational combination therapy being studied primarily for the treatment of lung squamous cell carcinoma. SHR-1701 is a bifunctional fusion protein that targets programmed death ligand 1 (PD-L1) and acts as a trap for transforming growth factor beta (TGFβ), thereby inhibiting both immune checkpoint and immunosuppressive TGFβ signaling pathways. Fluazopalil is presumed to be a small molecule drug, but specific details about its mechanism or class are not available in the provided sources. The combination aims to enhance antitumor immune responses by simultaneously blocking PD-L1-mediated immune evasion and TGFβ-driven immunosuppression[1][2][9]. Clinical trials are ongoing to evaluate efficacy and safety in first-line maintenance therapy for lung squamous cell carcinoma.
- Other names
- SHR-1701 combined with fluazopalilSHR1701 combined with fluazopalilSHR 1701 combined with fluazopalil
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)TGFB (GARP–latent transforming growth factor beta 1 complex)
Beyond the preview
Go deeper on SHR-1701 + fluazopalil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-1701 + fluazopalil.